Apelin Analogs
Peripheral Artery Disease (PAD), Neuromuscular Diseases, Sarcopenia
PreclinicalActive
Key Facts
Indication
Peripheral Artery Disease (PAD), Neuromuscular Diseases, Sarcopenia
Phase
Preclinical
Status
Active
Company
About Vasa Therapeutics
Vasa Therapeutics is a private, preclinical-to-clinical stage biotech developing transformative small molecule therapies for diseases of cardiovascular aging and related disorders. Its lead asset, VS-041, is a narrow-spectrum MMP-2/9 inhibitor with FDA Fast Track designation currently in a Phase 1 Proof-of-Mechanism (PoM) study for Heart Failure with Preserved Ejection Fraction (HFpEF). The company leverages a founder-led team with a strong drug development track record and is backed by seed investors and non-dilutive EU grant funding, positioning it to advance a pipeline targeting significant unmet needs in heart failure, peripheral artery disease, and sarcopenia.
View full company profile